Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Raches Ella(Bharat Biotech (India)), Siddhartha Dutta(Aligarh Muslim University), Siddarth Reddy(Bharat Biotech (India)), Pragya D. Yadav, Satyajit Mohapatra(Sri Ramachandra Medical Centre), Gajanan Sapkal(ICMR-National Institute of Virology), Sameer Bhate(Aligarh Muslim University), V. Bharge(People’s University), Suman Kanungo(Indian Council of Medical Research), Sai Prasad(Bharat Biotech (India)), Varsha Potdar(ICMR-National Institute of Virology), Savita Verma(Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences), Anil Kumar Pandey(ESIC Hospital), Archana Bandkar, C C Chaubal(All India Institute of Medical Sciences), Aparna H. Chavan, Pajanivel Ranganadin(Mahatma Gandhi Medical College and Research Institute), Deepak Chaudhary(Aligarh Muslim University), V. Aglawe(People’s University), Chandramani Singh(All India Institute of Medical Sciences), William C. Blackwelder, G. Balasubramaniyam(People’s University), Parth Desai(B.J. Medical College), P Basha(B.J. Medical College), Sagar Vivek Redkar, Nitin Anand, Krishna Mohan Vadrevu(Bharat Biotech (India)), Varun Bafna(People’s University), Samiran Panda(Indian Council of Medical Research), Krishna M. Ella(Bharat Biotech (India)), Priya Abraham(ICMR-National Institute of Virology), V. Bhavani(People’s University), Vamshi Sarangi(Bharat Biotech (India)), Balram Bhargava(Indian Council of Medical Research), Pradeep Aggarwal(International Atomic Energy Agency), Laxmi Kumari, Shameem Mohammad(Aligarh Muslim University), Nivedita Gupta(Indian Council of Medical Research), Sanjay Rai(All India Institute of Medical Sciences), Manish Multani, Dinesh Dhodi(Aligarh Muslim University), Abdullhameed May Ali, Ramesh Bhosale(B.J. Medical College), Prabhakar Reddy(Nizam's Institute of Medical Sciences), Parul Bhatt(B.J. Medical College), DV Chalapathy, N. Awad, Amit Suresh Bhate
Cited by 361
Related Papers
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
|Microorganisms|2021|658
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
|The Lancet Infectious Diseases|2021|364
How old is streamwater? Open questions in catchment transit time conceptualization, modelling and analysis
|Hydrological Processes|2010|355
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
|bioRxiv (Cold Spring Harbor Laboratory)|2021|268